Capital Asset Advisory Services’s DexCom DXCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-2,913
Closed -$204K 308
2025
Q4
$204K Buy
+2,913
New +$188K 0.01% 282
2024
Q2
Sell
-1,644
Closed -$228K 316
2024
Q1
$228K Sell
1,644
-29
-2% -$3.65K 0.01% 291
2023
Q4
$208K Buy
+1,673
New +$171K 0.01% 295
2023
Q3
Sell
-1,465
Closed -$201K 320
2023
Q2
$201K Buy
+1,465
New +$177K 0.01% 324
2023
Q1
Sell
-1,738
Closed -$206K 358
2022
Q4
$206K Buy
+1,738
New +$191K 0.02% 350
2022
Q2
Sell
-2,792
Closed -$357K 577
2022
Q1
$357K Sell
2,792
-776
-22% -$84.9K 0.04% 301
2021
Q4
$479K Sell
3,568
-624
-15% -$89.7K 0.05% 255
2021
Q3
$573K Sell
4,192
-892
-18% -$112K 0.06% 234
2021
Q2
$543K Buy
+5,084
New +$488K 0.06% 248

Other funds holding DXCM

Capital Asset Advisory Services's DXCM Position: Q1 2026 in Review

Capital Asset Advisory Services sold out of DexCom (DXCM) in Q1 2026, closing a stake of 2,913 shares — an estimated $204K sold.

Capital Asset Advisory Services first reported a position in DXCM in Q2 2021 and held it in 9 quarters. The position peaked at $573K in Q3 2021. 959 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Capital Asset Advisory Services reported no remaining DexCom position as of Q1 2026 after selling out during the quarter.
  • Capital Asset Advisory Services sold 2,913 DexCom shares in Q1 2026, an estimated $204K.
  • Capital Asset Advisory Services first reported a position in DexCom in Q2 2021 and held it in 9 quarters.
  • Capital Asset Advisory Services's DexCom position peaked at $573K in Q3 2021.
  • 959 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Capital Asset Advisory Services's 13F filing for Q1 2026, filed 24 Apr 2026.